Form 483

Belleview Biosciences LLC Form 483, 2014-04-01

FDA issued a Form 483 to Belleview Biosciences LLC on 2014-04-01 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Belleview Biosciences LLC · Brooksville, United States · Issued April 1, 2014

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

1 Apr 2014
21 CFR 211.84(d)(2)

Establish reliability of supplier's C of A

Cited by Jennifer A Robinson, Mizanne E Lewis, Michael H Tollon

1 Apr 2014
21 CFR 211.100(b)

Procedure Deviations Recorded and Justified

Cited by Jennifer A Robinson, Mizanne E Lewis, Michael H Tollon

1 Apr 2014
21 CFR 211.166(b)

Adequate number of batches on stability

Cited by Jennifer A Robinson, Mizanne E Lewis, Michael H Tollon

1 Apr 2014
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Jennifer A Robinson, Mizanne E Lewis, Michael H Tollon

1 Apr 2014
21 CFR 211.198(a)

Complaint Handling Procedure

Cited by Jennifer A Robinson, Mizanne E Lewis, Michael H Tollon

Inspected site

BBBelleview Biosciences LLCBrooksville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(b)Cited across public-safe Form 483 observations1x
21 CFR 211.113(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.204Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere